Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Biomarker-Based Tools for Treatment Response Decision Support of Bladder Cancer

Funder: National Cancer Institute

Funding period
USD 653 K
Funding amount
Abstract
PROJECT SUMMARY / ABSTRACT Bladder cancer is a common type of cancer that can cause substantial morbidity and mortality among both men and women. Bladder cancer causes over 16,870 deaths per year in the United States with 79,030 new bladder cancer cases diagnosed in 2017. A reliable assessment of the response to neoadjuvant therapy at an early stage is vital for identifying tumors that do not respond and allowing the patient a chance of alternative treatment. We have successfully developed a computer decision support system (CDSS-T) for monitoring of bladder cancer treatment response. A quantitative image analysis tool for bladder cancer (QIBC) that quantifies the bladder gross tumor volume (GTV) and image characteristics is an important component of CDSS-T. Advanced machine learning techniques are used to merge the GTV and radiomic biomarkers into an effective predictive model. The goal of this project is to validate the effectiveness of CDSS-T as an aid to the radiologists and the oncologists in assessment of bladder cancer change as a result of treatment through pilot clinical trials. We will (1) perform a preparatory clinical trial with the clinicians at UM, which will simulate the real prospective clinical trial with high quality retrospective data, (2) deploy the QIBC and CDSS-T tools at the three collaborating clinical sites, (3) use the QIBC and CDSS-T tools at the different clinical sites in the prospective pilot clinical trial (standard clinical workflow) utilizing the decision support in parallel to the standard clinical patient care, and (4) analyze the impact of the QIBC and CDSS-T tools on the clinicians' performance in the pilot clinical trial and assess the potential impact on clinical outcome. We hypothesize that this innovative approach can improve clinicians' accuracy, consistency and efficiency in bladder GTV estimation and assessment of treatment response. To test these hypotheses, we will perform the following specific tasks: (1) to evaluate the performance of the QIBC and CDSS-T tools on cases not previously used, new to the system, for both the prediction accuracy and the automatic standalone functionality, refine and optimize the design of the user interface based on clinicians' feedback after their hands-on experience with the system to ensure its practicality and robustness, familiarize clinicians with the performance of the CDSS-T tools and the interpretation of the CDSS-T outputs as a part of user training for the prospective pilot clinical trial, (2) to optimize the QIBC and CDSS-T tools for the clinical workflow at the different clinical sites based on the site clinicians' feedback in order to operate efficiently and in a standalone mode by clinicians, (3) to record the clinicians' predicted outcomes without and with the use of the tools during the pilot clinical trials, estimate the accuracy of assessing response to neoadjuvant chemotherapy in the current clinical treatment paradigm by comparing the estimated response to the histopathologically determined response after radical cystectomy, and (4) to statistically analyze the impact of the QIBC and CDSS-T tools on the performance of the clinicians in the pilot clinical trial and statistically assess the potential impact on clinical outcome.
Similar projects All >
Sorted by: Start Date
Project list item
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)

National Cancer Institute to NOAH M HAHN

USD 656,816
2019 - 2024
Project list item
INTRAVESICAL ONCOLYTIC THERAPY FOR BLADDER CANCER

National Cancer Institute to ROSA MARIA DIAZ, BRADLEY C. LEIBOVICH, LUKKANA SUKSANPAISAN

USD 1,081,593
2017 - 2020
Project list item
Proteogenomic characterization of muscle invasive bladder cancer to identify mechanisms of resistance and targets for therapy

Bladder Cancer Advocacy Network to Seth P. Lerner, Susan Hilsenbeck, Matthew James Ellis, Keith Syson Chan, Jonathan Michael Levitt, Sung Yun Jung, Anna Malovannaya, Bing Zhang

USD 300,000
2017 - 2019
Project list item
Development of personalized surgical algorithms for muscle-invasive bladder cancer patients

National Cancer Institute to PHILIP ABBOSH

USD 437,828
2017 - 2019
Project list item
Development of Novel Noninvasive Tests for Prognostic Predictions for Bladder Cancer

Congressionally Directed Medical Research Programs to Vinata B Lokeshwar

USD 608,000
2016 - 2017

System

Categories
  • FOR (ANZSRC)

    0801 Artificial Intelligence and Image Processing

  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Clinical Trials and Supportive Activities

  • RCDC

    Networking and Information Technology R&D

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    4.2 Evaluation of markers and technologies

  • Health Research Areas

    Clinical

  • Broad Research Areas

    Clinical Medicine and Science